European Commission Approves Kalydeco to Treat Cystic Fibrosis

Vertex Pharmaceuticals (Europe) Limited announced on 11/29/18 that the European Commission has granted approval of the label extension for Kalydeco (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR)